drugset / Trial / NCT04085887
Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures
Non-randomizedSequentialOpen-labelDiagnostic
Summary
The objective of the study is to assess safety of panitumumab-IRDye800 in pediatric patients undergoing brain surgery to remove suspected tumors.
Timeline
- Start
- 2026-08
- Primary completion
- 2028-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panitumumab-IRDye800 | Diagnostic / imaging agent | 0.006 mg/kg | Intravenous |
| Subject | Panitumumab-IRDye800 | Diagnostic / imaging agent | 0.25 mg/kg | Intravenous |
| Subject | Panitumumab-IRDye800 | Diagnostic / imaging agent | 0.5 mg/kg | Intravenous |
| Subject | Panitumumab-IRDye800 | Diagnostic / imaging agent | 1 mg/kg | Intravenous |